PUMA BIOTECHNOLOGY, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $97.1M | $-2.4M | $63.1M |
| FY2022 | $98.3M | $21.6M | $76.2M |
| FY2023 | $65.7M | $53.4M | $84.6M |
| FY2024 | $21.7M | $92.1M | $69.2M |
| FY2025 | $0 | $130.3M | $29.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $97.1M | $-2.4M | $63.1M |
| FY2022 | $98.3M | $21.6M | $76.2M |
| FY2023 | $65.7M | $53.4M | $84.6M |
| FY2024 | $21.7M | $92.1M | $69.2M |
| FY2025 | $0 | $130.3M | $29.6M |